Karen A. Canella

Array ( [id] => 18279538 [patent_doc_number] => 20230095010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION [patent_app_type] => utility [patent_app_number] => 17/887828 [patent_app_country] => US [patent_app_date] => 2022-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020604 [patent_doc_number] => 20220372103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/816496 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18226901 [patent_doc_number] => 20230065895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => POXVIRAL-BASED VACCINE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 AND METHODS USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/870070 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324913 [patent_doc_number] => 20230123041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => IMMUNOCONJUGATES AND METHODS [patent_app_type] => utility [patent_app_number] => 17/812869 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19578806 [patent_doc_number] => 12144888 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Immunoconjugates targeting CD46 and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/851340 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 29432 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18196519 [patent_doc_number] => 20230050038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => PDGF MUTANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/836684 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18165000 [patent_doc_number] => 20230031597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => BIASED IL2 MUTEINS METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/833235 [patent_app_country] => US [patent_app_date] => 2022-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17833235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18165000 [patent_doc_number] => 20230031597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => BIASED IL2 MUTEINS METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/833235 [patent_app_country] => US [patent_app_date] => 2022-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17833235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004951 [patent_doc_number] => 20220363717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/832246 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308720 [patent_doc_number] => 20230112620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA [patent_app_type] => utility [patent_app_number] => 17/831085 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18245981 [patent_doc_number] => 11602544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Compositions and methods for treating EGFR positive cancers [patent_app_type] => utility [patent_app_number] => 17/663758 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 40 [patent_no_of_words] => 62446 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867129 [patent_doc_number] => 20220289864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG [patent_app_type] => utility [patent_app_number] => 17/744575 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867129 [patent_doc_number] => 20220289864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG [patent_app_type] => utility [patent_app_number] => 17/744575 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867129 [patent_doc_number] => 20220289864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG [patent_app_type] => utility [patent_app_number] => 17/744575 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830135 [patent_doc_number] => 20220267439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Methods for Manipulating Phagocytosis Mediated by CD47 [patent_app_type] => utility [patent_app_number] => 17/736896 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19622932 [patent_doc_number] => 12161724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens [patent_app_type] => utility [patent_app_number] => 18/559201 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 83 [patent_no_of_words] => 88961 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 271 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308963 [patent_doc_number] => 20230112863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => IL-1 Binding Proteins [patent_app_type] => utility [patent_app_number] => 17/733303 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003599 [patent_doc_number] => 20220362365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => IMPROVED COMPOSITIONS AND METHODS FOR SHARED NEO-EPITOPE VACCINES [patent_app_type] => utility [patent_app_number] => 17/726946 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17726946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805865 [patent_doc_number] => 20220257700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS [patent_app_type] => utility [patent_app_number] => 17/659545 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17659545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058971 [patent_doc_number] => 11938164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Exosome-based cancer assays [patent_app_type] => utility [patent_app_number] => 17/714295 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 40 [patent_no_of_words] => 58598 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714295 [rel_patent_id] =>[rel_patent_doc_number] =>)